Journal
ONCOLOGIST
Volume 23, Issue 12, Pages E152-E158Publisher
WILEY
DOI: 10.1634/theoncologist.2018-0008
Keywords
Non-small cell lung cancer; Molecular alterations; Precision medicine; Reimbursement; Central and Southeastern Europe
Categories
Funding
- Ministry of Education, Youth and Sports, Czech Republic [CZ.02.1.01/0.0/0.0/16_013/0001674]
- AstraZeneca
Ask authors/readers for more resources
This article analyzes the availability of different diagnostic procedures of non-small cell lung cancer (NSCLC) and the reimbursement landscape of drugs for NSCLC in countries of central and southeastern Europe (CEE). A survey was conducted by the Central European Cooperative Oncology Group. Results of the survey show that both availability and reimbursement of diagnoses of molecular alterations in NSCLC, the detection of which is essential for therapeutic decisions, varies widely between countries of CEE. Not only is reflex testing often substituted by analyses performed only on demand, but reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. It was concluded that a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available